Table 1.
Patient demographics
| IV GCV vs. VGCV 900 | PO GCV vs. VGCV 450 mg | |
|---|---|---|
| Age | 39 (29–54) | 39 (28–64) |
| Gender (male/female) | ||
| Male | 4 | 4 |
| Female | 3 | 3 |
| Estimated GFR (mL/min) | Phase I: 66 (61–107) | Phase III: 64 (61–73) |
| Phase II: 62 (60–68) | Phase IV: 66 (56–102) | |
| Race | ||
| White | 3 | 3 |
| Black | 4 | 4 |
| CMV status | ||
| D−/R− | 2 | 2 |
| D+/R− | 2 | 2 |
| D+/R+ | 1 | 1 |
| D−/R+ | 2 | 2 |
| Induction therapy | ||
| Rabbit ATG | 5 | 5 |
| Alemtuzumab | 2 | 2 |
| Immunosuppresion | ||
| Sirolimus/tacrolimus | 5 | 5 |
| Tacrolimus | 2 | 2 |
Median with ranges in parentheses.
GFR = glomerular filtration rate.